B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
Joseph M Tuscano1,2, Jacob Sands1,21Hematology and Oncology, Veterans Affairs, Northern California Health Care System, California, USA; 2Division of Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, California, USAAbstract: The approach to treating autoimmune d...
Guardado en:
Autores principales: | Joseph M Tuscano, Jacob Sands |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b914087182554e769cf88838e423aaaa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rituximab therapy in Greek patients with rheumatoid arthritis
por: Haralampos M Moutsopoulos, et al.
Publicado: (2008) -
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis
por: Benucci M, et al.
Publicado: (2013) -
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
por: Re KA, et al.
Publicado: (2012) -
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
por: Lurati A, et al.
Publicado: (2013) -
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
por: Hasan E, et al.
Publicado: (2012)